Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NEUE Stock Forecast 2025-2026
$6.76
Current Price
$60.35M
Market Cap
Buy 0
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to NEUE Price Targets
+3.6%
To High Target of $7.00
+3.6%
To Median Target of $7.00
+3.6%
To Low Target of $7.00
NEUE Price Momentum
+0.1%
1 Week Change
+10.5%
1 Month Change
+9.7%
1 Year Change
-8.9%
Year-to-Date Change
-11.7%
From 52W High of $7.66
+78.4%
From 52W Low of $3.79
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching NeueHealth (NEUE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NEUE and similar high-potential opportunities.
Latest NEUE Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, NEUE has a neutral consensus with a median price target of $7.00 (ranging from $7.00 to $7.00). Currently trading at $6.76, the median forecast implies a 3.6% upside. This outlook is supported by 0 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Ben Hendrix at RBC Capital, projecting a 3.6% upside. Conversely, the most conservative target is provided by Ben Hendrix at RBC Capital, suggesting a 3.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NEUE Analyst Ratings
0
Buy
1
Hold
1
Sell
NEUE Price Target Range
Low
$7.00
Average
$7.00
High
$7.00
Current: $6.76
Latest NEUE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NEUE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 9, 2024 | RBC Capital | Ben Hendrix | Sector Perform | Maintains | $7.00 |
| Mar 13, 2024 | RBC Capital | Ben Hendrix | Sector Perform | Maintains | $8.00 |
| Aug 30, 2023 | Morgan Stanley | Underweight | Maintains | $0.00 | |
| Aug 14, 2023 | RBC Capital | Sector Perform | Maintains | $0.00 | |
| Jun 30, 2023 | Nephron Research | Buy | Upgrade | $0.00 | |
| Jun 15, 2023 | Barclays | Underweight | Downgrade | $0.00 | |
| May 30, 2023 | RBC Capital | Sector Perform | Maintains | $0.00 | |
| May 23, 2023 | Morgan Stanley | Underweight | Maintains | $0.00 | |
| May 22, 2023 | Morgan Stanley | Underweight | Maintains | $0.00 |
NeueHealth Inc. (NEUE) Competitors
The following stocks are similar to NeueHealth based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NeueHealth Inc. (NEUE) Financial Data
NeueHealth Inc. has a market capitalization of $60.35M with a P/E ratio of 1.2x. The company generates $936.66M in trailing twelve-month revenue with a -14.4% profit margin.
Revenue growth is -20.6% quarter-over-quarter, while maintaining an operating margin of -10.9% and return on equity of +48.3%.
Valuation Metrics
Market Cap
$60.35M
Enterprise Value
$1.16B
P/E Ratio
1.2x
PEG Ratio
-0.6x
Price/Sales
0.1x
Growth & Margins
Revenue Growth (YoY)
-20.6%
Gross Margin
+20.5%
Operating Margin
-10.9%
Net Margin
-14.4%
EPS Growth
-20.6%
Financial Health
Cash/Price Ratio
+159.8%
Current Ratio
0.6x
Debt/Equity
-0.6x
ROE
+48.3%
ROA
-6.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
NeueHealth Inc. (NEUE) Business Model
About NeueHealth Inc.
What They Do
Provides innovative healthcare solutions and services.
Business Model
The company operates by offering value-based healthcare services that include healthcare management, medical billing, and consulting. It generates revenue by optimizing healthcare providers' operations, improving efficiency and care quality, which is increasingly essential in the evolving healthcare landscape.
Additional Information
NeueHealth Inc. focuses on technology integration to streamline processes and enhance data accuracy for hospitals, clinics, and insurance entities. By contributing to the transition towards sustainable, patient-centered healthcare models, the company positions itself as a key player in the future of healthcare management and delivery systems.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
986
CEO
Mr. George Lawrence Mikan III
Country
United States
IPO Year
2021
Website
www.neuehealth.comNeueHealth Inc. (NEUE) Latest News & Analysis
Latest News
Quick Summary
NeueHealth (NYSE: NEUE) reported Q1 2025 results, highlighting significant consumer growth and continued Adjusted EBITDA profitability, indicating a strong start to the year.
Why It Matters
NeueHealth's strong Q1 results and Adjusted EBITDA profitability highlight its growth potential and effective healthcare model, signaling positive prospects for investors.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
NeueHealth, Inc. (NYSE: NEUE) will release its Q1 financial results on May 8, 2025, before market open, followed by a conference call at 8:00 AM ET. Pre-registration is required for phone participants.
Why It Matters
NeueHealth's upcoming financial results release is a key indicator of its performance and can influence stock price movements and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
KSF is investigating the proposed sale of NeueHealth (NYSE: NEUE) to an affiliate of New Enterprise Associates, offering shareholders $7.33 per share.
Why It Matters
The investigation into NeueHealth's sale could indicate potential issues with the transaction's fairness, affecting share value and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
NeueHealth, Inc (NYSE:NEUE) will hold its Q4 2024 results conference call on March 20, 2025, at 8:00 AM ET, featuring executives including CEO Mike Mikan and CFO Jay Matushak.
Why It Matters
The Q4 2024 earnings call will provide insights into NeueHealth's financial performance and future outlook, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
NeueHealth, Inc. (NYSE: NEUE) reported its strongest financial performance for Q4 and full year 2024. The company aims to leverage its consumer-centric care model for strategic growth in 2025.
Why It Matters
NeueHealth's strong financial performance in 2024 indicates successful execution of its business model, potentially leading to increased investor confidence and future growth opportunities.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
NeueHealth, Inc. (NYSE: NEUE) will release its Q4 and full year 2024 financial results on March 20, 2025, at 8:00 AM ET, followed by a conference call for participants.
Why It Matters
NeueHealth's upcoming financial results announcement and conference call could influence stock prices, providing insights into its performance and future outlook.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About NEUE Stock
What is NeueHealth Inc.'s (NEUE) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, NeueHealth Inc. (NEUE) has a median price target of $7.00. The highest price target is $7.00 and the lowest is $7.00.
Is NEUE stock a good investment in 2025?
According to current analyst ratings, NEUE has 0 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $6.76. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NEUE stock?
Wall Street analysts predict NEUE stock could reach $7.00 in the next 12 months. This represents a 3.6% increase from the current price of $6.76. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is NeueHealth Inc.'s business model?
The company operates by offering value-based healthcare services that include healthcare management, medical billing, and consulting. It generates revenue by optimizing healthcare providers' operations, improving efficiency and care quality, which is increasingly essential in the evolving healthcare landscape.
What is the highest forecasted price for NEUE NeueHealth Inc.?
The highest price target for NEUE is $7.00 from Ben Hendrix at RBC Capital, which represents a 3.6% increase from the current price of $6.76.
What is the lowest forecasted price for NEUE NeueHealth Inc.?
The lowest price target for NEUE is $7.00 from Ben Hendrix at RBC Capital, which represents a 3.6% increase from the current price of $6.76.
What is the overall NEUE consensus from analysts for NeueHealth Inc.?
The overall analyst consensus for NEUE is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $7.00.
How accurate are NEUE stock price projections?
Stock price projections, including those for NeueHealth Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 10:06 AM UTC